Evaluation of Clinical Decision Support System for Brain Metastasis Using Brain MR Images

Study Purpose

BT-M01 is a software that has been pre-learned based on a brain metastasis detection model using brain MR images, and clinical decision support system for brain metastasis by automatically analyzing brain MR images by assisting the medical team. The specific aims of this study are to evaluate efficacy of BT-M01 for brain metastasis compared to the sensitivity and false positive rates of radiologists group.

Recruitment Criteria

Accepts Healthy Volunteers

Healthy volunteers are participants who do not have a disease or condition, or related conditions or symptoms

No
Study Type

An interventional clinical study is where participants are assigned to receive one or more interventions (or no intervention) so that researchers can evaluate the effects of the interventions on biomedical or health-related outcomes.


An observational clinical study is where participants identified as belonging to study groups are assessed for biomedical or health outcomes.


Searching Both is inclusive of interventional and observational studies.

Interventional
Eligible Ages 19 Years and Over
Gender All
More Inclusion & Exclusion Criteria

Inclusion Criteria:

  • - Adults over 19 years old.
  • - Brain MR acquired.
  • - Positive group: A patient diagnosed with brain metastasis after a brain MR.
  • - Negative group: A normal person or a patient not diagnosed with brain metastasis after a brain MR.

Exclusion Criteria:

  • - Poor or incomplete brain MR image quality.
  • - A patient with other pathological lesion in brain.
- A patients with a history of primary brain tumors

Trial Details

Trial ID:

This trial id was obtained from ClinicalTrials.gov, a service of the U.S. National Institutes of Health, providing information on publicly and privately supported clinical studies of human participants with locations in all 50 States and in 196 countries.

NCT05573815
Phase

Phase 1: Studies that emphasize safety and how the drug is metabolized and excreted in humans.

Phase 2: Studies that gather preliminary data on effectiveness (whether the drug works in people who have a certain disease or condition) and additional safety data.

Phase 3: Studies that gather more information about safety and effectiveness by studying different populations and different dosages and by using the drug in combination with other drugs.

Phase 4: Studies occurring after FDA has approved a drug for marketing, efficacy, or optimal use.

N/A
Lead Sponsor

The sponsor is the organization or person who oversees the clinical study and is responsible for analyzing the study data.

Heuron Inc.
Principal Investigator

The person who is responsible for the scientific and technical direction of the entire clinical study.

Ji Eun Park, M.D.pH.D
Principal Investigator Affiliation Asan Medical Center
Agency Class

Category of organization(s) involved as sponsor (and collaborator) supporting the trial.

Industry
Overall Status Recruiting
Countries Korea, Republic of
Conditions

The disease, disorder, syndrome, illness, or injury that is being studied.

Brain Metastases
Arms & Interventions

Arms

Experimental: Positive group

A patient diagnosed with brain metastasis after a brain MR

Experimental: Negative group

A normal person or a patient not diagnosed with brain metastasis after a brain MR

Interventions

Device: - BT-M01

Clinical decision support system for detecting brain metastasis

Contact a Trial Team

If you are interested in learning more about this trial, find the trial site nearest to your location and contact the site coordinator via email or phone. We also strongly recommend that you consult with your healthcare provider about the trials that may interest you and refer to our terms of service below.

International Sites

Asan Medical Center, Seoul, Song-pa Gu, Korea, Republic of

Status

Recruiting

Address

Asan Medical Center

Seoul, Song-pa Gu, 05505

Site Contact

Yoomi Kim

[email protected]

+82 032-429-8507

Stay Informed & Connected